In vitro activities of pazufloxacin, a novel injectable quinolone, againstbacteria causing infections in obstetric and gynecological patients

T-3762 is an injectable new quinolone with a broad spectrum of antibacteria l activity. Pazufloxacin (T-3761) is an active form of T-3762. The minimal inhibitory concentrations (MICs) of pazufloxacin for 50% of the clinical is olates tested were 3.13 mu g/ml for Streptococcus agalactiae, 6.25 mu g/ml for Gardnerella vaginalis, 0.025 mu g/ml for Escherichia coli, 0.78 mu g/ml for Pseudomonas aeruginosa, 6.25 mu g/ml for Peptostreptococcus magnus, 6. 25 mu g/ml for Bacteroides fragilis and 12.5 mu g/ml for Prevotella bivia. The MICs of T-3762 for 90% of the clinical isolates tested were 3.13 mu g/m l for S. agalactiae, 6.25 mu g/ml for G. vaginalis, 0.10 mu g/ml for E. col i, 12.5 mu g/ml for P. aeruginosa, 25 mu g/ml for P. magnus, 12.5 mu g/ml f or B. fragilis and 25 mu g/ml for P. bivia. The results of this study sugge st that, subject to confirmation by clinical trials, T-3762, in combination with an agent with reliable activity against anaerobic bacteria, is suitab le as an empirical therapy of patients with obstetric and gynecological inf ections.